Skip to main content
The Scientific World Journal logoLink to The Scientific World Journal
. 2013 Nov 3;2013:258758. doi: 10.1155/2013/258758

Radiation Sterilization of Anthracycline Antibiotics in Solid State

A Kaczmarek 1, J Cielecka-Piontek 2, P Garbacki 2,*, K Lewandowska 3, W Bednarski 3, B Barszcz 3, P Zalewski 2, W Kycler 4, I Oszczapowicz 5, A Jelińska 2
PMCID: PMC3835845  PMID: 24298208

Abstract

The impact of ionizing radiation generated by a beam of electrons of 25–400 kGy on the stability of such analogs of anthracycline antibiotics as daunorubicin (DAU), doxorubicin (DOX), and epidoxorubicin (EPI) was studied. Based on EPR results, it was established that unstable free radicals decay exponentially with the half-time of 4 days in DAU and DOX and 7 days in EPI after irradiation. Radiation-induced structural changes were analyzed with the use of spectrophotometric methods (UV-Vis and IR) and electron microscope imaging (SEM). A chromatographic method (HPLC-DAD) was applied to assess changes in the contents of the analogs in the presence of their impurities. The study showed that the structures of the analogs did not demonstrate any significant alterations at the end of the period necessary for the elimination of unstable free radicals. The separation of main substances and related substances (impurities and potential degradation products) allowed determining that no statistically significant changes in the content of particular active substances occurred and that their conversion due to the presence of free radicals resulting from exposure to an irradiation of 25 kGy (prescribed to ensure sterility) was not observed.

1. Introduction

Anthracycline antibiotics belong to the group of anticancer drugs. They were originally isolated from cultures of Streptomyces. Anthracyclines are widely used in the treatment of neoplastic diseases such as leukemia, breast cancer, and AIDS-related Kaposi's sarcoma. They also demonstrate activity against tumors of the ovaries, lung, testes, prostate, cervix, bladder, and Ewing's sarcoma [13]. The most widely used anthracyclines are doxorubicin (DOX), daunorubicin (DAU), and epidoxorubicin (EPI) [46] (Figure 1). Their low bioavailability necessitates parenteral administration [7, 8], which requires sterility [9] obtained mainly by filtration. Given the considerable exposure of medical personnel to anthracycline antibiotics and their adsorption to most surfaces, especially those of sterilization filters, there is a need to find new sterilization methods that do not rely on filtration. Although radiation sterilization is an effective alternative, the structure of drugs may alter as a consequence of exposure to irradiation. The aglycone attached to the aminosugar with a glycoside bond may be prone to cleavage resulting from electron transfer within the molecule. Stability studies demonstrated degradation of anthracycline antibiotics in solutions, under the influence of increased temperature and when exposed to light in the solid state as well as a consequence of combining chemotherapy with radiotherapy [1015]. Regarding the effects of radiation sterilization on anthracycline antibiotics, only DOX was studied in that respect with a focus on the impact of a standard dose of 25 kGy on its stability [16]. As DAU and EPI are widely used in anticancer pharmacotherapy, those antibiotics also require analysis of their vulnerability to ionizing radiation.

Figure 1.

Figure 1

Chemical structures of daunorubicin, doxorubicin, and epidoxorubicin.

The aim of this work was to assess the possibility of applying radiation sterilization to DOX, DAU, and EPI as active substances or conversion-induced impurities.

2. Materials and Methods

2.1. Samples

DOX, DAU, and EPI were synthesized at the Institute of Biotechnology and Antibiotics, Department of Modified Antibiotics, Warsaw, Poland. They were reddish powders, freely soluble in water and methanol. Sodium lauryl sulfate, phosphoric acid, and all other chemicals were obtained from Merck KGaA (Germany) and were of analytical or high-performance liquid chromatographic grade.

2.2. Irradiation

0.025 g samples of each substance were placed in 3 mL colorless glass vials that were closed with plastic stoppers. The samples in the vials were exposed to beta irradiation in a linear electron accelerator LAE 13/9 (9.96 MeV electron beam and 6.2 μA current intensity) until they absorbed doses of 25, 50, 100, 200, and 400 kGy.

2.3. Electron Paramagnetic Resonance (EPR) Spectroscopy

Detection of free radicals and determination of their concentration were carried out using a Bruker ELEXSYS 500 spectrometer (X-band) at 297 K. EPR spectra were recorded as a first derivative of the absorption signal. The number of free radicals was calculated using the integration procedure described elsewhere [17].

2.4. UV-Vis Spectroscopy

Chemical changes in nonirradiated and irradiated samples were analyzed by using a UV-Vis Varian Carry 100 spectrophotometer. 2 mg of each sample was dissolved in 20.0 mL of methanol. 1.0 mL of the so-obtained solution was diluted to 10.0 mL with methanol. The final concentration of the solutions was 0.01 mg/mL. Absorption spectra of the so-prepared solutions were recorded in the wavelength range 190–900 nm.

2.5. IR Spectroscopy

IR spectra of nonirradiated and irradiated anthracyclines were taken with the use of a Thermo Scientific Nicolet iS10 spectrophotometer with the Omnic software. The infrared transmittance spectra of the crystalline samples were recorded after a time necessary to achieve plateaus in EPR study, in the frequency range from 400 to 7500 cm−1, at room temperature.

2.6. HPLC Analysis

An HPLC Waters Alliance e2695 system was used for chromatographic separation of the degradation products of nonirradiated and irradiated DOX, DAU and EPI samples. All the samples (1 mg/mL) were dissolved in the mobile phase. A Symmetry C18 (250 × 4.6 mm, 5 μm) analytical column was employed as a stationary phase. The mobile phase consisted of solution A (acetonitrile) and solution B (2.88 g of sodium lauryl sulfate and 2.25 g of phosphoric acid(V) 85% in 1000 mL) (50 : 50, v : v). UV detection was performed at 254 nm. The flow rate was 1.0 mL/min. The injected volume was 5 μL.

2.7. Theoretical Analysis

All the calculations were made by using the Gaussian 03 package [18]. In order to interpret the experimental results of IR absorption scattering, quantum chemical calculations were performed based on a density functional theory (DFT) method with the B3LYP hybrid functional and 6-31G(d,p) basis set.

3. Results and Discussions

The first EPR analysis was performed 1 day after irradiation for samples exposed to a dose of 25 kGy. DOX, DAU, and EPI irradiated at 25 kGy contained about 3.94 × 1015 spins/g, 1.37 × 1015 spins/g, and 2.44 × 1015 spins/g, respectively. Exponential decay of unstable free radical was observed with the half-time of 4 days in DAU and DOX and 7 days in EPI after irradiation. The EPR signals of the sterilized anthracycline antibiotics were very weak. The plateaus of free radical concentrations versus time for DOX and DAU appeared after about 10 days, whereas for EPI after 20 days. EPR spectra after these periods consisted approximately of only stable free radicals.

The analytical study was conducted during a period when only stable free radicals were detected by EPR. The impact of an irradiation dose size on the structure of DAU, DOX, and EPI was studied at 0, 25, 50, 100, 200, and 400 kGy without the presence of unstable free radical in EPR spectra. By using UV-Vis spectroscopy the location and the intensity of the absorption maximum were determined, whereas IR spectroscopy was employed to establish the intensity, location, and type of characteristic vibrations. For the DAU, DOX, and EPI samples no significant changes in the location (~289 nm, ~233 nm, and 221 nm) or intensity of the absorption maximum were recorded (Figures 2, 3, and 4). The spectra of their nonirradiated and irradiated samples did not show any essential differences in the value of absorbance. All samples exhibited two absorption maxima, at 233 nm and 251 nm. The IR spectra of DOX, DAU, and EPI were compared with the theoretical spectra based on the density functional theory. The main characteristic vibrations obtained from the IR spectra are collected in Table 1. The conformation between the calculated and experimental spectra is quite good. The most significant is the region between 700 and 1800 cm−1, where intense and characteristic bands related to intramolecular vibrations of the molecules are observed, including the deformation of rings as well as stretching of various C–C bonds (Figures 5, 6, and 7). Vibrational spectra of the nonirradiated and irradiated samples of the three samples are very similar. We did not observe any change in the position and shape of the bands. This suggests that the radiation sterilization does not influence the stability of the DOX, DAU, and EPI. Similar results were received by comparing SEM images of the nonirradiated and irradiated samples. Taking into account the biological activity of the most important impurities specified by Ph. Eur. [9], changes in the concentration of the main substances in the presence of those impurities were analyzed (Figures 8, 9, 10, 11, 12, and 13). By separating the compounds to be examined from the impurities, it was possible to assess changes in their content before and after irradiation at 25 kGy. It was found that exposure to such a dose of radiation did not produce any changes in the concentrations of the main substances or the impurities.

Figure 2.

Figure 2

UV spectra of unirradiated and gamma irradiated daunorubicin.

Figure 3.

Figure 3

UV spectra of unirradiated and gamma irradiated doxorubicin.

Figure 4.

Figure 4

UV spectra of unirradiated and gamma irradiated epidoxorubicin.

Table 1.

Main characteristic vibrational modes of daunorubicin (DAU), doxorubicin (DOX), and epidoxorubicin (EPI) observed in experimental and calculated spectra.

Calculation (cm−1) Experimental (cm−1) Band assignment
DAU DOX EPI DAU DOX EPI
723 736 736 764 761 761 C–C–C b in a ring + def. aglycone group + breathing tetrahydropyran ring in aminosugar group + NH2w

752 754 749 795 795 795 NH2   w + C–C–C b in aminosugar group + C–H w at d ring and in aminosugar group

776 773 774 816 804 805 C–C–C b in a ring + def. aglycone group + breathing tetrahydropyran ring in aminosugar group + CH2r at d ring

931 930 935 940 939 939 C–O–H b at c ring + C–H w in aminosugar group

959 957 951 955 949 949 C–C–C b in d ring + NH2   w + CH w at d ring and aminosugar group

984 CH3w in COCH3 group

1010 1008 1006 986 990 989 Breathing aglycone group + CH2   r + NH2   r + CH3   w in COCH3 + CH2   w in COCH2OH

1021 1029 1032 1008 1005 1005 Breathing a ring + def. aglycone group + C–O s at a ring + C–O–H b at c ring + NH2   w + CH3   w in COCH3 group

1079 1078 1065 1070 1072 1072 C–O s between tetrahydropyran ring and O–H group in aminosugar group

1105 1104 1104 1085 1089 1089 C–O s in metoxy group at a ring + C–C–C b in a ring + CH2   r

1123 1123 1122 1109 1114 1114 C–O s in tetrahydropyran ring + C–O s in glycosidic bond + C–C s in d ring + C–H w in CH3 in aminosugar group

1137 1139 1136 1109 1114 1114 C–C s in d ring and in tetrahydropyran ring in aminosugar group + C–H b at d ring and in tetrahydropyran ring in aminosugar group + CH3   w in COCH3 group + C–O s in COCH2OH group

1157 1157 1156 1153 1143 1143 C–O s in glycosidic bond + C–O s between tetrahydropyran ring and O–H group in aminosugar group + C–H r in CH3 in aminosugar group + def. d ring

1206 1205 1200 1194 1201 1201 C–O s in glycosidic bond + C–C s I d ring + C–H b at d ring and aminosugar group

1226 1225 1221 1205 1211 1211 CH2   t at d ring + breathing a ring + C–O–H b at c ring

1239 1239 1235 1235 C–O–H b in COCH2OH group

1278 1275 1275 1262 1263 1263 C–O–H b at c ring + C–C s in aglycone group + CH2   t in COCH2OH group

1291 1290 1293 1289 1284 1285 C–O–H b at c ring + breathing a and c ring

1317 1317 1318 1289 1284 1285 Breathing c ring + C–O s at c ring + C–O s at a ring + CH2w at a ring +C–H w at d ring

1329 1329 1330 1317 1318 1318 C–O s at a ring + breathing a and c ring

1367 1367 1366 1374 1374 1374 C–C–C b in d ring + C–C s in a and b ring + C–O s at c ring + C–O– b at c ring

1404 CH3  sc in COCH3 group

1425 1427 1423 1404 1413 1413 O–C–H b + N–C–H b

1476 1476 1478 1474 1471 1472 C–O s at c ring + def. c ring + CH3   umbrella mode at a ring + C–O–H b at c ring

1502 1502 1505 1506 1507 1507 C–O–H b at c ring + CH3  sc at a ring + C–C s in aglycone group

1524 1524 1527 1525 1524 C–O–H b at c ring + CH3  sc at a ring + C–C s in aglycone group

1614 1615 1615 1576 1582 1581 C–C s in c ring + C–O–H b at c ring + C=O s at b ring + C–C s in a ring

1640 1640 1642 1576 1582 1581 C–C s in a ring + C–O–H b at c ring + CH3   w at a ring

1661 1663 1663 1617 1616 1616 NH2  sc

1688 1688 1688 1617 1616 1616 C=O s at b ring + C–O–H b at c ring

1744 1744 1745 1707 1717 1717 C=O s at b ring

1791 1808 1807 1716 1730 1730 C=O s at d ring

2967–3237 2844–3108 C–H s

3009 3010 2960 2878 2896 2896 O–H s at c ring

3488 3488 3485 N–H s symmetric

3566 3566 3571 N–H s antisymmetric

3630 3634 3639 3161 3326 3329 O–H s

3791 3788 3785 3527 3527 O–H s

3809 3801 O–H s

3831 3831 3545 3545 O–H s in COCH2OH group

Vibrational modes—s: stretching, b: bending, w: wagging, sc: scissoring, r: rocking, and t: twisting.

Figure 5.

Figure 5

FT-IR spectra of unirradiated and gamma irradiated daunorubicin.

Figure 6.

Figure 6

FT-IR spectra of unirradiated and gamma irradiated doxorubicin.

Figure 7.

Figure 7

FT-IR spectra of unirradiated and gamma irradiated epidoxorubicin.

Figure 8.

Figure 8

HPLC profile of unirradiated daunorubicin.

Figure 9.

Figure 9

HPLC profile of irradiated daunorubicin (25 kGy).

Figure 10.

Figure 10

HPLC profile of unirradiated doxorubicin.

Figure 11.

Figure 11

HPLC profile of irradiated doxorubicin (25 kGy).

Figure 12.

Figure 12

HPLC profile of unirradiated epidoxorubicin.

Figure 13.

Figure 13

HPLC profile of irradiated epidoxorubicin (25 kGy).

Slight alterations were registered when the samples of DAU, DOX, and EPI were exposed to greater doses of radiation. Under such conditions, EPI demonstrated the greatest content change, and the presence of unstable free radicals was noted for the longest period of time. It was also proved, by observing the mass balance, that the main substances did not convert into unknown impurities. Similar studies of some tetracycline analogs showed that the aglycon was stable when irradiated at 25 kGy and that changes occurred when greater radiation doses were applied [19]. It may therefore be proposed that not only a modification of the aglycon structure but also its ability to bind with a sugar moiety of specific stereoisomerism are the factors that stabilize the structures of analogs of anthracycline antibiotics.

4. Conclusions

The current study of the impact of radiation sterilization on the stability of DAU, DOX, and EPI demonstrates that this kind of sterilization may be an alternative to filtration recommended for sterilizing analogs of anthracycline antibiotics. The effect of radiation sterilization on the stability of DAU, DOX, and EPI depends on the structure of a particular compound. With regard to those analogs, it is important to assay the postirradiation content of the main substance in the presence of all possible related substances in order to determine whether other degradation products or postirradiation conversion occur.

References

  • 1.Hortobágyi GN. Anthracyclines in the treatment of cancer: an overview. Drugs. 1997;54(4):1–7. doi: 10.2165/00003495-199700544-00003. [DOI] [PubMed] [Google Scholar]
  • 2.Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologie developments in antitumor activity and cardiotoxicity. Pharmacological Reviews. 2004;56(2):185–229. doi: 10.1124/pr.56.2.6. [DOI] [PubMed] [Google Scholar]
  • 3.Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Seminars in Oncology. 1992;19(6):670–686. [PubMed] [Google Scholar]
  • 4.Cortés-Funes H, Coronado C. Role of anthracyclines in the era of targeted therapy. Cardiovascular Toxicology. 2007;7(2):56–60. doi: 10.1007/s12012-007-0015-3. [DOI] [PubMed] [Google Scholar]
  • 5.Pagani O, Sessa C, Martinelli G, et al. Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer. Annals of Oncology. 1999;10(5):539–545. doi: 10.1023/a:1026437731354. [DOI] [PubMed] [Google Scholar]
  • 6.Romanini A, Tanganelli L, Carnino F, et al. First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients. Gynecologic Oncology. 2003;89(3):354–359. doi: 10.1016/s0090-8258(03)00128-8. [DOI] [PubMed] [Google Scholar]
  • 7.Wang E, Lew K, Barecki M, Casciano CN, Clement RP, Johnson WW. Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4. Chemical Research in Toxicology. 2001;14(12):1596–1603. doi: 10.1021/tx010125x. [DOI] [PubMed] [Google Scholar]
  • 8.Fakhoury M, Litalien C, Medard Y, et al. Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age. Drug Metabolism and Disposition. 2005;33(11):1603–1607. doi: 10.1124/dmd.105.005611. [DOI] [PubMed] [Google Scholar]
  • 9.European Pharmacopoeia. 7th edition. Strasbourg, France: Council of Europe; 2010. [Google Scholar]
  • 10.Sobczak A, Jelińska A, Leśniewska M, Firlej A, Oszczapowicz I. Stability of epidoxorubicin in solid state. Journal of Pharmaceutical and Biomedical Analysis. 2010;54(4):869–872. doi: 10.1016/j.jpba.2010.10.024. [DOI] [PubMed] [Google Scholar]
  • 11.Cielecka-Piontek J, Jelińska A, Zajac M, Sobczak M, Bartold A, Oszczapowicz I. A comparison of the stability of doxorubicin and daunorubicin in solid state. Journal of Pharmaceutical and Biomedical Analysis. 2009;50(4):576–579. doi: 10.1016/j.jpba.2008.12.029. [DOI] [PubMed] [Google Scholar]
  • 12.Jelińska A, Uszak J, Cielecka-Piontek J, et al. Stability of [(N-pyrrolidine)metylene]daunorubicin in aqueous solutions. Reaction Kinetics and Catalysis Letters. 2009;98(1):69–75. [Google Scholar]
  • 13.Zalewski P, Zając M, Jelińska A, Cielecka-Piontek J, Oszczapowicz I. Stability study of anticancer agent N-[(Hexahydroazepin-1-yl)methyl] daunorubicin in aqueous solutions using HPLC method. Asian Journal of Chemistry. 2011;23(2):835–838. [Google Scholar]
  • 14.Cielecka-Piontek J, Jelińska A, Dołhań A, et al. Stability of new anticancer agents in intravenous solutions’. Asian Journal of Chemistry. 2012;24(2):769–772. [Google Scholar]
  • 15.Jelińska A, Zaj̧c M, Cielecka-Piontek J, et al. Validation of a stability indicating LC-UV method for [(N-morpholine) methylene]daunorubicin hydrochloride. Chromatographia. 2008;67(1):107–111. [Google Scholar]
  • 16.Varshney L, Dodke PB. Radiation effect studies on anticancer drugs, cyclophosphamide and doxorubicin for radiation sterilization. Radiation Physics and Chemistry. 2004;71(6):1103–1111. [Google Scholar]
  • 17.Morkunas I, Bednarski W. Fusarium oxysporum-induced oxidative stress and antioxidative defenses of yellow lupine embryo axes with different sugar levels. Journal of Plant Physiology. 2008;165(3):262–277. doi: 10.1016/j.jplph.2007.01.020. [DOI] [PubMed] [Google Scholar]
  • 18.Frisch MJ, Trucks GW, Schlegel HB, et al. Gaussian 03. Wallingford, Conn, USA: Gaussian, Inc.; 2004. (Revision D.01). [Google Scholar]
  • 19.Jocobs GP. The radation-sterilization of tetracycline hydrochloride. Journal of Pharmacy and Pharmacology. 1976;28(supplement 7) [PubMed] [Google Scholar]

Articles from The Scientific World Journal are provided here courtesy of Wiley

RESOURCES